AIM: The expression of the telomerase subunits such as human telomerase reverse transcriptase (hTERT) and human telomerase RNA component (hTR) may be associated with tumor development and progression. We evaluated the relationship between mRNA quantification of both hTERT and hTR and clinicopathologic parameters in bladder cancer. METHODS: We examined the mRNA expression of hTERT and hTR in 29 specimens with bladder cancer (Grade: Grade I, 9 cases; Grade II, 13 cases and Grade III, 7 cases. Stage: pTa-pT1, 18 cases; pT2-T4, 11 cases). We immediately froze all of specimens obtained during TUR-Bt and isolated the total RNA from each specimen. We measured the quantity of hTERT, hTR and GAPDH mRNA by a real-time reverse transcription-polymerase chain reaction method based on TaqMan technology. RESULTS: The hTERT/GAPDH mRNA ratio and hTERT mRNA/total RNA in superficial bladder tumor was significantly lower than in invasive bladder tumor. The hTR/GAPDH mRNA ratio and hTR mRNA/total RNA in superficial tumor were significantly lower than in invasive bladder tumor. The hTERT mRNA expression significantly correlated with tumor grade, but the hTR mRNA expression did not correlate with tumor grade. There was no significant difference in the hTERT/GAPDH mRNA ratio and hTR mRNA/total RNA according to multiplicity of bladder tumor. CONCLUSIONS: Our results demonstrated that the expression of hTERT mRNA correlated with the progression of stage and grade in bladder cancer. The quantitative analysis of hTERT and hTR mRNA might be a marker for clinicopathologic parameters in bladder cancer.
AIM: The expression of the telomerase subunits such as humantelomerase reverse transcriptase (hTERT) and human telomerase RNA component (hTR) may be associated with tumor development and progression. We evaluated the relationship between mRNA quantification of both hTERT and hTR and clinicopathologic parameters in bladder cancer. METHODS: We examined the mRNA expression of hTERT and hTR in 29 specimens with bladder cancer (Grade: Grade I, 9 cases; Grade II, 13 cases and Grade III, 7 cases. Stage: pTa-pT1, 18 cases; pT2-T4, 11 cases). We immediately froze all of specimens obtained during TUR-Bt and isolated the total RNA from each specimen. We measured the quantity of hTERT, hTR and GAPDH mRNA by a real-time reverse transcription-polymerase chain reaction method based on TaqMan technology. RESULTS: The hTERT/GAPDH mRNA ratio and hTERT mRNA/total RNA in superficial bladder tumor was significantly lower than in invasive bladder tumor. The hTR/GAPDH mRNA ratio and hTR mRNA/total RNA in superficial tumor were significantly lower than in invasive bladder tumor. The hTERT mRNA expression significantly correlated with tumor grade, but the hTR mRNA expression did not correlate with tumor grade. There was no significant difference in the hTERT/GAPDH mRNA ratio and hTR mRNA/total RNA according to multiplicity of bladder tumor. CONCLUSIONS: Our results demonstrated that the expression of hTERT mRNA correlated with the progression of stage and grade in bladder cancer. The quantitative analysis of hTERT and hTR mRNA might be a marker for clinicopathologic parameters in bladder cancer.
Authors: Anne Sofie Brems-Eskildsen; Karsten Zieger; Helle Toldbod; Cherie Holcomb; Russell Higuchi; Francisco Mansilla; Pia P Munksgaard; Michael Borre; Torben F Ørntoft; Lars Dyrskjøt Journal: BMC Cancer Date: 2010-11-24 Impact factor: 4.430
Authors: Jonine D Figueroa; Yuanqing Ye; Afshan Siddiq; Montserrat Garcia-Closas; Nilanjan Chatterjee; Ludmila Prokunina-Olsson; Victoria K Cortessis; Charles Kooperberg; Olivier Cussenot; Simone Benhamou; Jennifer Prescott; Stefano Porru; Colin P Dinney; Núria Malats; Dalsu Baris; Mark Purdue; Eric J Jacobs; Demetrius Albanes; Zhaoming Wang; Xiang Deng; Charles C Chung; Wei Tang; H Bas Bueno-de-Mesquita; Dimitrios Trichopoulos; Börje Ljungberg; Françoise Clavel-Chapelon; Elisabete Weiderpass; Vittorio Krogh; Miren Dorronsoro; Ruth Travis; Anne Tjønneland; Paul Brenan; Jenny Chang-Claude; Elio Riboli; David Conti; Manuela Gago-Dominguez; Mariana C Stern; Malcolm C Pike; David Van Den Berg; Jian-Min Yuan; Chancellor Hohensee; Rebecca Rodabough; Geraldine Cancel-Tassin; Morgan Roupret; Eva Comperat; Constance Chen; Immaculata De Vivo; Edward Giovannucci; David J Hunter; Peter Kraft; Sara Lindstrom; Angela Carta; Sofia Pavanello; Cecilia Arici; Giuseppe Mastrangelo; Ashish M Kamat; Seth P Lerner; H Barton Grossman; Jie Lin; Jian Gu; Xia Pu; Amy Hutchinson; Laurie Burdette; William Wheeler; Manolis Kogevinas; Adonina Tardón; Consol Serra; Alfredo Carrato; Reina García-Closas; Josep Lloreta; Molly Schwenn; Margaret R Karagas; Alison Johnson; Alan Schned; Karla R Armenti; G M Hosain; Gerald Andriole; Robert Grubb; Amanda Black; W Ryan Diver; Susan M Gapstur; Stephanie J Weinstein; Jarmo Virtamo; Chris A Haiman; Maria T Landi; Neil Caporaso; Joseph F Fraumeni; Paolo Vineis; Xifeng Wu; Debra T Silverman; Stephen Chanock; Nathaniel Rothman Journal: Hum Mol Genet Date: 2013-10-24 Impact factor: 6.150
Authors: Radmila V Karpova; Vladimir V Levkin; Tatyana Y Degtyarevskaya; Ksenia S Russkova; Alexey A Yushkevich; Arthur A Tevosyan Journal: J Gastrointest Oncol Date: 2019-12